Category: Market/Novel Tech

Month: 16 Apr 2012

Issue: not yet available

ThromboGenics raises EUR77.8M in a private placement

ThromboGenics NV (NYSE Euronext Brussels: THR), a biopharmaceutical company focused on the development of ocular treatments has announced the closure of a EUR77.8 million private placement. The private placement allowed ThromboGenics to place 3,244,675 new shares with domestic and international investors at a price of EUR24 per share, representing a 3.5% discount on the company’s previous closing price. The placement brings the total number of shares after issuance to 35,691,432, listed on NYSE Euronext Brussels.

Back to previous

Related News

Gearoid Tuohy

editor

by Dr. Gearóid Tuohy   Dear EURETINA Members,   A very warm welcome to the December 4th, 2017 edition of EURETINA’s web-based digital magazine, “EURETINA Brief”. EURETINA are delighted to continue our delivery of up-to-date summary briefs on a range of topics of interest to retinal clinicians, specialists and researchers across Europe. This resource is […]